Day One Biopharmaceuticals

Aging Populations And Regulatory Momentum Will Boost OJEMDA Uptake

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

24 Aug 25

Updated

24 Aug 25

AnalystHighTarget's Fair Value

US$34.00

78.1% undervalued

24 Aug

US$7.46

-47.0%

9.4%

-47.0%

9.4%

Author's Valuation

US$34.0

78.1% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$34.0

78.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

27.48%

Biotech revenue growth rate

11.84%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$116.88m

Earnings '28

37.89x

PE Ratio '28

US$4.43b

Market Cap '28

US$4.43b

Market Cap '28

107.34m

No. shares '28

US$41.26

Share Price '28

US$41.26 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$33.89

Fair Value '25